The company said GAAP earnings for Q2 2024 were $713 million ($1.12 per diluted share), compared with a loss of $603 million ($0.95) in Q2 2023. Adjusted earnings were $567 million ($0.89) for Q2 2023, versus $594 million ($0.94).

1. 01

   The company said GAAP earnings for Q2 2024 were $713 million ($1.12 per diluted share), compared with a loss of $603 million ($0.95) in Q2 2023. Adjusted earnings were $567 million ($0.89) for Q2 2023, versus $594 million ($0.94).

2. 02

   Sempra listed the impact from foreign currency and inflation on its monetary positions in Mexico at $(152) million and net unrealized losses on derivatives at $6 million as reconciling items between GAAP and adjusted earnings for Q2 2024. The company said the amounts for Q2 2023 were $93 million and $(102) million, respectively.

3. 03

   The company reported net cash provided by operating activities of $2,520 million for the first six months of 2024 (6 months), compared with $3,737 million in the first six months of 2023. Capital expenditures for the same period were $3,830 million (2023: $4,282 million).

4. 04

   The company updated its full-year 2024 GAAP EPS guidance to $4.74 to $5.04 and reaffirmed its adjusted EPS guidance of $4.60 to $4.90. It also said Oncor reached a settlement in principle on a System Resiliency Plan of about $3 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.